Yaklai Kiangyada, Kunasol Chanon, Suparan Kanokphong, Apaijai Nattayaporn, Chitapanarux Taned, Pattanakuhar Sintip, Chattipakorn Nipon, Chattipakorn Siriporn C
Sriphat Medical Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Muang 50200, Chiang Mai, Thailand.
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):109046. doi: 10.4292/wjgpt.v16.i3.109046.
Irritable bowel syndrome with predominant constipation (IBS-C) is a chronic gastrointestinal disorder that significantly impacts the quality of life of patients and currently lacks a definitive treatment. The use of electroacupuncture (EA) has demonstrated clinical efficacy in treating IBS-C and the gut-brain axis modulation, though its mechanisms remain unclear.
To investigate gut-brain-microbiota axis alteration and EA-associated microbial changes in IBS-C patients and treatment responders.
This study consisted of two phases. The first phase was a cross-sectional study recruiting sixteen IBS-C patients and 16 healthy controls. Baseline fecal samples were collected to assess gut microbiota profiles between the two groups. The second phase was an observational longitudinal study in which the 16 IBS-C patients underwent nine EA sessions over one month. Gut microbiota profiles and clinical outcomes were assessed post-treatment course and at a one-month follow-up.
IBS-C patients exhibited significant gut dysbiosis, as indicated by altered beta diversity compared to healthy controls. EA significantly improved clinical outcomes and gut dysbiosis, with sustained therapeutic effects and normalization of neurotransmitter-related metabolic pathways observed at one-month follow-up. Notably, the gut bacterium was positively associated with symptom improvement, suggesting its potential as a predictive biomarker of EA responsiveness.
These findings support the integration of EA into IBS-C management and highlight as a candidate microbial biomarker for treatment response.
以便秘为主的肠易激综合征(IBS-C)是一种慢性胃肠道疾病,严重影响患者的生活质量,目前缺乏明确的治疗方法。电针(EA)在治疗IBS-C和调节肠-脑轴方面已显示出临床疗效,但其机制尚不清楚。
研究IBS-C患者及治疗反应者的肠-脑-微生物群轴改变及与电针相关的微生物变化。
本研究包括两个阶段。第一阶段为横断面研究,招募16例IBS-C患者和16名健康对照。收集基线粪便样本以评估两组之间的肠道微生物群谱。第二阶段为观察性纵向研究,16例IBS-C患者在一个月内接受9次电针治疗。在治疗疗程结束后及随访1个月时评估肠道微生物群谱和临床结局。
与健康对照相比,IBS-C患者表现出明显的肠道生态失调,表现为β多样性改变。电针显著改善了临床结局和肠道生态失调,在随访1个月时观察到持续的治疗效果和神经递质相关代谢途径的正常化。值得注意的是,肠道细菌与症状改善呈正相关,表明其作为电针反应性预测生物标志物的潜力。
这些发现支持将电针纳入IBS-C的管理,并突出了 作为治疗反应候选微生物生物标志物的作用。